Close Menu

NEW YORK – Adaptive Biotechnologies announced Thursday that it has received expanded clearance from the US Food and Drug Administration for its clonoSeq assay to assess minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL.)

The next-generation sequencing-based test can now be used to detect and monitor MRD from blood or bone marrow samples and is the first and only FDA-cleared in vitro diagnostic for MRD monitoring in CLL, the firm said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.